nct_id: NCT05702229
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2023-01-27'
study_start_date: '2023-01-16'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: AZD7789'
  - drug_name: 'Drug: Capecitabine'
  - drug_name: 'Drug: Volrustomig'
  - drug_name: 'Drug: 5-Fluorouracil'
  - drug_name: 'Drug: XELOX'
  - drug_name: 'Drug: AZD0901'
  - drug_name: 'Drug: Rilvegostomig'
  - drug_name: 'Drug: FOLFOX'
long_title: An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the
  Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations
  in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal
  Junction Adenocarcinoma
last_updated: '2025-11-17'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE2
principal_investigator: NA
principal_investigator_institution: AstraZeneca
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 240
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* 18 years or older at the time of signing the ICF.'
- '* Body weight \> 35 kg.'
- '* Previously untreated for unresectable or metastatic gastric or gastroesophageal
  junction adenocarcinoma.'
- '* Has measurable target disease assessed by the Investigator based on RECIST 1.1.'
- '* ECOG PS zero or one.'
- '* Life expectancy of at least 12 weeks.'
- '* Adequate organ and bone marrow function.'
- '* Has central lab confirmed Claudin18.2 status at screening from archival tumour
  collected within past 24 months or from a fresh biopsy when Substudy 3, Substudy
  4 or Substudy 6 is open for recruitment.'
- 'Exclude - Exclusion Criteria:'
- Exclude - * Participants with HER2-positive (3+ by IHC, or 2+ by IHC and positive
  by in situhybridisation) or indeterminate gastric or GEJ carcinoma.
- Exclude - * Untreated or progressive CNS metastatic disease, any leptomeningeal
  disease, or cord compression.
- Exclude - * Participants with ascites which cannot be controlled with appropriate
  interventions.
- Exclude - * Active infectious diseases, including tuberculosis, HIV infection, or
  hepatitis A/B/C.
- Exclude - * Uncontrolled intercurrent illness.
- Exclude - * Active or prior documented autoimmune or inflammatory disorders requiring
  systemic treatment with steroids or other immunosuppressive treatment.
- Exclude - * History of another primary malignancy.
- Exclude - * Previous treatment with an immune-oncology agent.
- Exclude - * Previous treatment with any modalities of Claudin18.2 target therapy
  or MMAE exposure (when Substudy 3, Substudy 4, or Substudy 6 is open for recruitment).
short_title: Novel Combinations in Participants With Locally Advanced Unresectable
  or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: AstraZeneca
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: This is a Phase II, open-label, multi-drug, multi-centre study designed to
  assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity
  of novel combination therapies in participants with locally advanced unresectable
  or metastatic gastric or GEJ adenocarcinoma.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Substudy 1
      arm_internal_id: 0
      arm_description: Volrustomig plus XELOX (oxaliplatin and capecitabine) or FOLFOX
        (oxaliplatin and 5-FU/CF)
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Volrustomig'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: FOLFOX'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: XELOX'
        level_internal_id: 2
        level_suspended: N
    - arm_code: Substudy 2
      arm_internal_id: 1
      arm_description: Rilvegostomig plus XELOX (oxaliplatin and capecitabine) or
        FOLFOX (oxaliplatin and 5-FU/CF)
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Rilvegostomig'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: FOLFOX'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: XELOX'
        level_internal_id: 2
        level_suspended: N
    - arm_code: Substudy 3
      arm_internal_id: 2
      arm_description: AZD0901 plus volrustomig and 5-fluorouracil or capecitabine
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Volrustomig'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: AZD0901'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: 5-Fluorouracil'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Capecitabine'
        level_internal_id: 3
        level_suspended: N
    - arm_code: Substudy 4
      arm_internal_id: 3
      arm_description: AZD0901 plus rilvegostomig and 5-fluorouracil or capecitabine
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Rilvegostomig'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: AZD0901'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: 5-Fluorouracil'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Capecitabine'
        level_internal_id: 3
        level_suspended: N
    - arm_code: Substudy 5
      arm_internal_id: 4
      arm_description: AZD7789 plus XELOX (oxaliplatin and capecitabine) or FOLFOX
        (oxaliplatin and 5-FU/CF)
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: FOLFOX'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: XELOX'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: AZD7789'
        level_internal_id: 2
        level_suspended: N
    - arm_code: Substudy 6
      arm_internal_id: 5
      arm_description: AZD0901 plus AZD7789 and 5-fluorouracil or capecitabine
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: AZD7789'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: AZD0901'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: 5-Fluorouracil'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Capecitabine'
        level_internal_id: 3
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        her2_status: Negative
        disease_status:
        - Unresectable
        - Metastatic
        oncotree_primary_diagnosis: Esophagogastric Adenocarcinoma
